^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) + oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma
Published date:
02/18/2022
Excerpt:
Of the 2,483 patients (male 53.7%, median-age 66 years) studied, 266 tumors (10.7%) were KRAS-WT….Real-world evidence reveals a survival advantage of KRAS-WT patients in overall cohorts as well as in patients treated with gemcitabine/nab-paclitaxel or 5FU/oxaliplatin.
DOI:
10.1158/1078-0432.CCR-21-3581
